

Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104

Website: www.novartis.in

June 2, 2022

The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

Scrip Code: 500672

Dear Sir/ Madam,

Sub.: Disclosure of Related Party Transactions for the half year ended March 31, 2022 under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith the disclosure of Related Party Transactions on standalone basis for the half year ended March 31, 2022.

This is for your information and records.

Thanking you

Yours sincerely,

For Novartis India Limited

Nikhil Malpani

Company Secretary and Compliance Officer

(A) Enterprise where control exists

Holding Company and Ultimate Holding Company

Novartis AG, Switzerland

(B) Other Related Parties with whom the company had transactions during the year and/or the previous year

(i) Fellow Subsidiaries

Novartis Asia Pacific Pharmaceutical Pte Ltd, Singapore

Novartis Healthcare Private Limited, India Novartis Holding AG, Switzerland Novartis Pharma Services AG, Switzerland Novartis Pharma AG, Switzerland Sandoz Private Limited, India

(ii) List of other related parties (Post-employment benefit plan of Novartis India Limited)

Novartis India Limited Employees' Provident Fund

Novartis India Limited Superannuation Fund

(C) Key Management

Personnel

S. Murdeshwar C. Snook J. Hiremath @ S. Martyres @

Sanker Parmeswaran @

Monaz Noble*

@ Independent Directors

* Non Independent Non Executive Director

	Half year ended 31st March, 2022	
	in ₹ million	
(a) Holding Company and Ultimate Holding Company		
Royalty Expense	15.3	
Balance as at the year end -		
Outstanding Payable	17.4	

/L.	17-11	C.L. dialianian
(D)	renow	Subsidiaries

	Half year ended 31st March, 2022
	in ₹ million
Purchases of Stock-in-Trade	Supres:
Novartis Pharma AG	479.8
	479.8
ale of Services	
Novartis Healthcare Private Limited	33.3
Sandoz Private Limited	1.7
	35.0
Commission Income	
Novartis Healthcare Private Limited	56.4
	56.4
cility Usage charges recovery	
Novartis Healthcare Private Limited	18.2
	18.2
ervices Availed	
Novartis Healthcare Private Limited	19.2
Novartis Pharma AG	0.6
	19.8
le of Fixed assets	
Novartis Healthcare Private Limited	40.0
	40.0



Novartis India Limited

Novartis Holding AG 11.2	Purchase of Restricted Shares of Novartis AG on behalf of		
Expenses paid by Company on behalf of the related party Novartis Pharma Services AG 29.7 20.7 31st March, 2022 in ₹ million Balances as at the year end - Outstanding Receivables Novartis Healthcare Private Limited 97.8 Novartis Pharma AG 9.3 Novartis Pharma Services AG 9.3 Outstanding Payables Novartis Healthcare Private Limited 68.7 Novartis Holding AG 11.2 Novartis Holding AG 11.1 Novartis Pharma AG 230.7 310.6 c) Post Employment Benefit Plans of Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund 0.3 Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits Commission to Independent Directors 5 titing fees to Independent Directors 1.4			
Expenses paid by Company on behalf of the related party Novartis Pharma Services AG 29.7 29.7 29.7 31st March, 2022 in ₹ million Balances as at the year end - Outstanding Receivables Novartis Pharma AG Novartis Pharma AG Novartis Pharma AG Novartis Pharma Services AG 9.3 145.7 Outstanding Payables Novartis Healthcare Private Limited Novartis Healthcare Private Limited Novartis Healthcare Private Limited Novartis Pharma AG Novartis India Limited Post Employment Benefit Plans of Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund Novartis India Limited Employees' Provident Fund Short-term employee benefits Novartis Independent Directors Short-term employee benefits Commission to Independent Directors Stiting fees to Independent Directors 1.4	Novartis Holding AG		
Novartis Pharma Services AG 29.7 22.7		11.2	
Balances as at the year end - Outstanding Receivables Novartis Healthcare Private Limited Novartis Pharma AG Novartis Pharma Services AG 9.3	Expenses paid by Company on behalf of the related party		
Balances as at the year end - Outstanding Receivables Novartis Healthcare Private Limited Novartis Pharma AG Novartis Pharma Services AG Novartis Pharma Services AG Outstanding Payables Novartis Healthcare Private Limited Novartis Holding AG Novartis Holding AG Novartis Pharma AG Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund Novartis India Limited Employees' Provident Fund Novartis India Limited Employees' Provident Fund Short-term employee benefits Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4	Novartis Pharma Services AG	29.7	
Balances as at the year end - Outstanding Receivables Novartis Healthcare Private Limited Novartis Pharma AG Novartis Pharma Services AG Novartis Pharma Services AG Novartis Pharma Services AG Novartis Healthcare Private Limited Novartis Healthcare Private Limited Novartis Holding AG Novartis Holding AG Novartis Holding AG Novartis Pharma AG Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund Novartis India Limited Employees' Provident Fund Novartis India Limited Employees' Provident Fund Short-term employee benefits Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4		29.7	
Balances as at the year end - Outstanding Receivables Novartis Healthcare Private Limited 97.8 Novartis Pharma AG 38.6 Novartis Pharma Services AG 9.3 145.7 Outstanding Payables Novartis Healthcare Private Limited 68.7 Novartis Healthcare Private Limited Novartis Holding AG 11.2 Novartis Pharma AG 230.7 310.6 c) Post Employment Benefit Plans of Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund 0.3 Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 3.0 d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits 7.2 Commission to Independent Directors 2.8 Sitting fees to Independent Directors 1.4		31st March, 2022	
Novartis Healthcare Private Limited Novartis Pharma AG Novartis Pharma Services AG Novartis Pharma Services AG Outstanding Payables Novartis Healthcare Private Limited Novartis Healthcare Private Limited Novartis Healthcare Private Limited Novartis Holding AG Novartis Pharma AG Outstanding Payables Novartis Holding AG Novartis Pharma AG Post Employment Benefit Plans of Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund Novartis India Limited Employees' Provident Fund Novartis India Limited Employees' Provident Fund Advances to Novartis India Limited Employees' Provident Fund Advances to Novartis India Limited Employees' Provident Fund 3.0 3.0 Half year ended 31st March, 2022 in ₹ million Short-term employee benefits 7.2 Commission to Independent Directors Sitting fees to Independent Directors 1.4		in ₹ million	
Novartis Healthcare Private Limited 97.8	2000 A 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5		
Novartis Pharma AG 9.3 Novartis Pharma Services AG 9.3 145.7 Outstanding Payables Novartis Healthcare Private Limited 68.7 Novartis Holding AG 11.2 Novartis Pharma AG 230.7 310.6 Post Employment Benefit Plans of Novartis India Limited		(95)(25)(20)	
Novartis Pharma Services AG 9.3 145.7			
Outstanding Payables Novartis Healthcare Private Limited Novartis Holding AG Novartis Pharma AG Novartis Pharma AG Novartis Pharma AG Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund Novartis India Limited Employees' Provident Fund 3.0 3.0 Half year ended 31st March, 2022 in ₹ million Short-term employee benefits Commission to Independent Directors 2.8 Sitting fees to Independent Directors 1.4			
Novartis Healthcare Private Limited Novartis Holding AG Novartis Pharma AG Novartis Pharma AG Novartis Pharma AG Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund Novartis India Limited Employees' Provident Fund 3.0 3.0 Advances to Advances	Novartis Pharma Services AG		
Novartis Healthcare Private Limited Novartis Holding AG Novartis Pharma AG Novartis Pharma AG Novartis Pharma AG Post Employment Benefit Plans of Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund Novartis India Limited Employees' Provident Fund Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund Novartis India Limited Employees' Provident Fund Novartis India Limited Employees' Provident Fund Advances to Novartis India Limited Employees' Provident Fund Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4		145.7	
Novartis Holding AG Novartis Pharma AG 230.7 310.6 C) Post Employment Benefit Plans of Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund 0.3 Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 A) Novartis India Limited Employees' Provident Fund 3.0 A) Wey Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits 7.2 Commission to Independent Directors Sitting fees to Independent Directors 1.4	Outstanding Payables		
Novartis Pharma AG C) Post Employment Benefit Plans of Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund O.3 Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 A) Novartis India Limited Employees' Provident Fund Alf year ended 31st March, 2022 in ₹ million Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4	Novartis Healthcare Private Limited	68.7	
c) Post Employment Benefit Plans of Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund O.3 Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 A) Wey Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4	Novartis Holding AG	11.2	
C) Post Employment Benefit Plans of Novartis India Limited Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund 0.3 Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 3.0 d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits 7.2 Commission to Independent Directors Sitting fees to Independent Directors 1.4		230.7	
Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund 0.3 Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits 7.2 Commission to Independent Directors Sitting fees to Independent Directors 1.4		310.6	
Half year ended 31st March, 2022 in ₹ million Novartis India Limited Employees' Superannuation Fund 0.3 Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits 7.2 Commission to Independent Directors Sitting fees to Independent Directors 1.4	(c) Post Employment Benefit Plans of Novartis India Limited		
Novartis India Limited Employees' Superannuation Fund 0.3 Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 3.0 d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4	(*)	Half year ended 31st March, 2022	
Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 3.0 d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4		in ₹ million	
Balances as at the year end - Advances to Novartis India Limited Employees' Provident Fund 3.0 3.0 3.0 (d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4	Novartis India Limited Employees' Superannuation Fund		
Advances to Novartis India Limited Employees' Provident Fund 3.0 3.0 d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4		0.3	
Advances to Novartis India Limited Employees' Provident Fund 3.0 3.0 d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits Commission to Independent Directors Sitting fees to Independent Directors 1.4	Balances as at the year end -		
d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits 7.2 Commission to Independent Directors 2.8 Sitting fees to Independent Directors 1.4	그런 얼마 없다면 하다 하는 것이 되었다면 하다 하는데 그렇게 하다.		
d) Key Management Personnel Compensation Half year ended 31st March, 2022 in ₹ million Short-term employee benefits 7.2 Commission to Independent Directors 2.8 Sitting fees to Independent Directors 1.4		3.0	
Half year ended 31st March, 2022 in ₹ million Short-term employee benefits 7.2 Commission to Independent Directors 2.8 Sitting fees to Independent Directors 1.4		3.0	
Short-term employee benefits 7.2 Commission to Independent Directors 2.8 Sitting fees to Independent Directors 1.4	(d) Key Management Personnel Compensation		
Short-term employee benefits 7.2 Commission to Independent Directors 2.8 Sitting fees to Independent Directors 1.4			
Commission to Independent Directors 2.8 Sitting fees to Independent Directors 1.4	And the characteristic field content a research (Active	Salti-Anjacova Byo Harris	
Sitting fees to Independent Directors			
total compensation 11.4			
	Total compensation	11.4	

Notes:

1) No amounts have been written off/provided for or written back in respect of amounts receivable from or payable to the related parties except as disclosed above.

2) Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash.

